Homepage

Biodesix, Inc.

BDSX NASDAQ Categories PDF
Healthcare · Medical - Diagnostics & Research · United States · Updated May 10, 8:17pm
$15.32
Price
$115.7M
Market Cap
273
Employees
0.43
Beta
Scott Hutton
CEO
Business Description

Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also offers GeneStrat ddPCR and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions; and GeneStrat NGS (NGS) test, a 72-hour blood-based NGS test. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado.

Business History
Price Overview
Last updated: May 11, 2026 1:56pm (just now)
$15.86
+0.54 (+3.49%)
Day Range
$14.81 – $15.86
52-Week Range
$3.44 – $20.21
50-Day MA
$14.43
200-Day MA
$9.83
Volume
51,035.00
Analyst Price Targets
Low $3.00
Consensus $8.67
High $20.00
(3 analysts)
Share Structure
Outstanding 7,551,109.00
Float 2,958,616.00
Free Float 39.2%
Moderate free float — 39.2% of shares trade freely, ~60.8% held by insiders/institutions
Reasonable but insiders still hold a significant stake. This can be positive (skin in the game) but may limit liquidity during sell-offs.
Small absolute float (3.0M shares) — even with a decent free float %, volume can be thin. Check average daily volume before sizing a position.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
Period Revenue Net Income Net Margin YoY/QoQ
Key Metrics
API Direct from provider CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALC
Stock Price / EPS (Diluted)
-3.28
Stock Price: $15.32
EPS (Diluted): -4.67
P/B Ratio (Price vs net asset value)
API
Stock Price / Book Value Per Share
-20.83
Stock Price: $15.32
Total Equity: -$2.47M
Shares: 7,551,000
EV/EBITDA (Total value vs operating profit)
API
Enterprise Value / EBITDA
-8.84
Market Cap: $115.68M
Total Debt: $72.85M
Cash: $18.99M
EBITDA: -$21.88M
Enterprise Value (Takeover price (cap + debt - cash))
API
Market Cap + Total Debt - Cash
$105.2M
Market Cap: $115.68M
Total Debt: $72.85M
Cash: $18.99M
Gross Margin (Revenue left after direct costs)
API
Gross Profit / Revenue
75.2%
Gross Profit: $66.59M
Revenue: $88.50M
Operating Margin (Revenue left after all operations)
API
Operating Income / Revenue
-31.5%
Operating Income: -$27.87M
Revenue: $88.50M
Net Margin (Revenue left as actual profit)
API
Net Income / Revenue
-39.8%
Net Income: -$35.27M
Revenue: $88.50M
ROE (Profit from shareholder equity)
API
Net Income / Total Equity
-2,101.4%
Net Income: -$35.27M
Total Equity: -$2.47M
ROIC (Profit from all invested capital)
API
NOPAT / Invested Capital
-30.6%
Operating Income: -$27.87M
Tax Rate: 0.0%
Equity: -$2.47M
Total Debt: $72.85M
Cash: $18.99M
Current Ratio (Can it pay short-term bills)
API
Current Assets / Current Liabilities
1.86
Current Assets: $32.52M
Current Liabilities: $17.44M
Debt/Equity (Leverage — debt vs equity)
CALC
Total Debt / Total Equity
-29.56
Short-Term Debt: $1.37M
Long-Term Debt: $71.48M
Total Debt: $72.85M
Total Equity: -$2.47M
Rev/Share (Top-line per share)
CALC
Revenue / Shares Outstanding
$11.72
Revenue: $88.50M
Shares: 7,551,000
Book Value/Share (Net assets per share)
CALC
(Total Assets - Total Liabilities) / Shares
$-0.33
Total Equity: -$2.47M
Shares: 7,551,000
FCF/Share (Real cash generated per share)
CALC
(Operating Cash Flow + CapEx) / Shares
$-3.14
Operating CF: -$23.27M
CapEx: -$403,000
Shares: 7,551,000
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
API
Last Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $15.32
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$35.27M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares BDSX against LLM-researched typical ranges for its industry. One research call per industry, cached indefinitely — every stock in the same industry reuses the same baseline.
Deep Analysis

Pre-flight intelligence scans the company first, then routes to the right analytical methods.

0 Company Classification — What type of company is this?
1 Industry Landscape — Where is the industry headed?
2 Company Momentum — Where is this company trending?
3 Forward Projection — 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a DCF Valuation — Present value of future cash flows
4b Earnings Power Value — Floor value — worth with zero growth
4c Anchored PE — Industry PE adjusted for growth differential
4d Reverse DCF — What growth is the market pricing in?
4e Revenue-Based DCF — For growth/narrative companies (skip if mature earner)
4f Anchored P/S — Price-to-Sales peer comparison (skip if mature earner)
4g Scenario Analysis — Bull / Base / Bear (skip if mature earner)
4h Dividend Discount Model — For dividend/income stocks only
4i Book Value Analysis — For deep value / turnaround stocks only
4j Insider Activity — Are insiders buying or selling?
4f Cash Flow Quality — How trustworthy is the FCF?
4g Debt Maturity Risk — Can it handle its debt?
4h Macro Environment — Rates, market valuation, volatility
4i Sector Intelligence — How does this company compare within its sector?
4j Revenue Confidence — How reliable is the growth projection?
4k Sensitivity Analysis — How fragile is the fair value estimate?
4l Sector Demand Cycle — Is the sector in a boom, steady state, or contraction?
5 AI Investigation — Adaptive research engine (Claude)
5b Thesis Evaluation — What does the market believe? (narrative/platform stocks only)
6 Valuation Synthesis — Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Metric 2021 2022 2023 2024 2025
Revenue $54.5M $38.2M $49.1M $71.3M $88.5M
Cost of Revenue $30.5M $14.2M $13.0M $15.6M $21.9M
Gross Profit $24.0M $24.1M $36.1M $55.8M $66.6M
Operating Expenses $64.9M $74.6M $77.4M $90.2M $94.4M
Operating Income -$40.9M -$50.6M -$41.3M -$34.5M -$27.9M
Net Income -$43.2M -$65.4M -$52.1M -$42.9M -$35.3M
EBITDA -$35.5M -$51.5M -$37.1M -$29.2M -$21.9M
EPS $-31.60 $-31.00 $-12.80 $-6.60 $-4.67
EPS (Diluted) — — — — —
Balance Sheet (Annual)
Metric 2021 2022 2023 2024 2025
Cash & Equivalents $32.7M $43.1M $26.3M $26.2M $19.0M
Total Current Assets $43.6M $53.3M $39.7M $39.5M $32.5M
Total Assets $76.1M $92.9M $99.1M $97.2M $87.5M
Current Liabilities $29.0M $22.8M $33.4M $14.3M $17.4M
Long-Term Debt $10.0M $25.0M $35.2M $36.4M $71.5M
Total Liabilities $56.4M $72.3M $94.5M $76.4M $89.9M
Total Equity $19.7M $20.6M $4.6M $20.9M -$2.5M
Retained Earnings -$302.0M -$367.4M -$419.6M -$462.5M -$497.8M
Cash Flow (Annual)
Metric 2021 2022 2023 2024 2025
Operating Cash Flow -$28.2M -$45.0M -$22.9M -$48.6M -$23.3M
Capital Expenditure -$2.5M -$3.5M -$23.1M -$3.2M $-403,000
Free Cash Flow -$30.8M -$48.5M -$45.9M -$51.9M -$23.7M
Acquisitions (net) $0 $0 $0 $0 $0
Debt Repayment — — — — —
Dividends Paid — — — — —
Stock Buybacks $0 $0 $0 $0 $0
Net Change in Cash -$29.5M $10.4M -$16.8M $-39,000 -$7.3M
Analyst Estimates (Annual)
Metric 2027 2028 2029 2030
Revenue $132.7M
$132.2M – $133.3M
 $155.6M
$154.3M – $157.0M
 $182.1M
$180.6M – $183.7M
 $198.0M
$196.3M – $199.7M
EBITDA -$81.3M
-$81.7M – -$81.0M
 -$95.3M
-$96.2M – -$94.5M
 -$111.6M
-$112.6M – -$110.6M
 -$121.3M
-$122.4M – -$120.3M
Net Income -$13.8M
-$13.9M – -$13.6M
 -$10.5M
-$11.6M – -$9.5M
 -$4.5M
-$4.5M – -$4.4M
 -$2.3M
-$2.4M – -$2.3M
EPS — — — —
Growth Trends (YoY %)
Metric 2022 2023 2024 2025
Revenue Growth -29.9% +28.5% +45.3% +24.1%
Gross Profit Growth +0.3% +50.0% +54.5% +19.5%
Operating Income Growth -23.6% +18.3% +16.6% +19.2%
Net Income Growth -51.6% +20.3% +17.7% +17.9%
EBITDA Growth -45.3% +28.0% +21.3% +25.1%
Insider Trading (Recent)
Date Insider Type Shares Price Value
2026-03-31 PATIENCE JOHN M-Exempt 1,361.00 $0.00 $0
2026-03-31 PATIENCE JOHN M-Exempt 1,361.00 $0.00 $0
2026-02-20 Pestano Gary Anthony M-Exempt 1,528.00 $0.00 $0
2026-02-23 Pestano Gary Anthony S-Sale 556.00 $12.78 $7,103
2026-02-20 Pestano Gary Anthony M-Exempt 1,528.00 $0.00 $0
2026-02-20 O'Kane Kieran M-Exempt 1,469.00 $0.00 $0
2026-02-23 O'Kane Kieran S-Sale 535.00 $12.78 $6,835
2026-02-20 O'Kane Kieran M-Exempt 1,469.00 $0.00 $0
2026-02-20 Cowie Robin Harper M-Exempt 1,469.00 $0.00 $0
2026-02-23 Cowie Robin Harper S-Sale 535.00 $12.78 $6,835
2026-02-20 Cowie Robin Harper M-Exempt 1,469.00 $0.00 $0
2026-02-20 Vazquez Chris M-Exempt 563.00 $0.00 $0
2026-02-20 Vazquez Chris M-Exempt 563.00 $0.00 $0
2026-02-23 Vazquez Chris S-Sale 211.00 $12.78 $2,696
2026-02-20 Hutton Scott M-Exempt 4,844.00 $0.00 $0
2026-02-23 Hutton Scott S-Sale 1,490.00 $12.78 $19,036
2026-02-20 Hutton Scott M-Exempt 4,844.00 $0.00 $0
2026-02-09 O'Kane Kieran M-Exempt 1,600.00 $0.00 $0
2026-02-10 O'Kane Kieran S-Sale 584.00 $10.08 $5,889
2026-02-09 O'Kane Kieran M-Exempt 1,527.00 $0.00 $0
Community AI Feedback
Sign in to Contribute
No community reviews yet for BDSX. Be the first — export the analysis to your AI and contribute back.
My Notes personal — only you see this
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.193 · 1946f027 · 2026-05-08 18:57:27